Shares of TransMedics fell after the company lowered its full-year revenue outlook.
The stock fell 8% to $77.92 in after-hours trading Monday. For the year, shares are up almost 8%.
The Andover, Mass.-based medical technology company said it expects full-year revenue between $428 million to $432 million, lower than its previous outlook of $425 million to $445 million in October. Analysts polled by Facset expected 431.9 million.
The company also named Gerardo Hernandez as its new chief financial officer, effective Monday.